These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 23881723)

  • 41. Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis.
    Mendoza YP; Rodrigues SG; Bosch J; Berzigotti A
    Dig Liver Dis; 2020 Sep; 52(9):958-965. PubMed ID: 32736898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cirrhosis and its complications: evidence based treatment.
    Nusrat S; Khan MS; Fazili J; Madhoun MF
    World J Gastroenterol; 2014 May; 20(18):5442-60. PubMed ID: 24833875
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.
    Sharma P; Sharma BC; Sarin SK
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):526-31. PubMed ID: 20009938
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A short cut to predict the clinical response to beta-blocker therapy in cirrhosis?
    Merkel C
    J Hepatol; 2009 Aug; 51(2):268-70. PubMed ID: 19515449
    [No Abstract]   [Full Text] [Related]  

  • 45. Hepatic venous pressure gradient and outcomes in cirrhosis.
    Ripoll C
    J Clin Gastroenterol; 2007; 41 Suppl 3():S330-5. PubMed ID: 17975485
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis.
    Labenz C; Nagel M; Toenges G; Kuchen R; Schattenberg JM; Hilscher M; Huber Y; Marquardt JU; Labenz J; Galle PR; Wörns MA
    Eur J Intern Med; 2020 Dec; 82():83-89. PubMed ID: 32873457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study.
    Kang SH; Lee M; Kim MY; Lee JH; Jun BG; Kim TS; Choi DH; Suk KT; Kim YD; Cheon GJ; Kim DJ; Baik SK
    Hepatol Int; 2021 Apr; 15(2):424-436. PubMed ID: 33860898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis.
    Gu Y; Yang X; Liang H; Li D
    BMC Gastroenterol; 2019 Dec; 19(1):231. PubMed ID: 31888534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of HCV-related end-stage liver disease in HIV-coinfected patients.
    Merchante N; Jiménez-Saenz M; Pineda JA
    AIDS Rev; 2007; 9(3):131-9. PubMed ID: 17982938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gut microflora in the pathogenesis of the complications of cirrhosis.
    Garcia-Tsao G; Wiest R
    Best Pract Res Clin Gastroenterol; 2004 Apr; 18(2):353-72. PubMed ID: 15123075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis.
    Senzolo M; Cholongitas E; Burra P; Leandro G; Thalheimer U; Patch D; Burroughs AK
    Liver Int; 2009 Sep; 29(8):1189-93. PubMed ID: 19508620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of portal hypertension and its complications.
    Jaffe DL; Chung RT; Friedman LS
    Med Clin North Am; 1996 Sep; 80(5):1021-34. PubMed ID: 8804373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Therapy of liver cirrhosis. Managing complications with fingertip control].
    Mörk H
    MMW Fortschr Med; 2001 Jul; 143(26-27):34-7. PubMed ID: 11481913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beta-blockers to prevent esophageal varices--an unfulfilled promise.
    Mukherjee S; Sorrell MF
    N Engl J Med; 2005 Nov; 353(21):2288-90. PubMed ID: 16306528
    [No Abstract]   [Full Text] [Related]  

  • 55. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.
    Garcia-Tsao G; Lim JK;
    Am J Gastroenterol; 2009 Jul; 104(7):1802-29. PubMed ID: 19455106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improved survival with nonselective beta blockers.
    Thalheimer U; Bosch J; Patch D; Burroughs A
    Hepatology; 2008 Dec; 48(6):2091-2. PubMed ID: 19030169
    [No Abstract]   [Full Text] [Related]  

  • 57. [Liver cirrhosis--current aspects of diagnosis and therapy.2: therapy of complications].
    Held C
    Z Arztl Fortbild (Jena); 1990; 84(16):819-24. PubMed ID: 2171234
    [No Abstract]   [Full Text] [Related]  

  • 58. [Liver cirrhosis].
    Bahr MJ; Manns MP
    Internist (Berl); 1999 Dec; 40(12):1308-22. PubMed ID: 10642918
    [No Abstract]   [Full Text] [Related]  

  • 59. A pill a day can improve survival in patients with advanced cirrhosis.
    Runyon BA
    Gastroenterology; 2007 Sep; 133(3):1029-31. PubMed ID: 17854604
    [No Abstract]   [Full Text] [Related]  

  • 60. [Current problems in the prevention and treatment of infections in patients with cirrhosis].
    Bellot P; Jara Pérez López N; Martínez Moreno B; Such J
    Gastroenterol Hepatol; 2010 Dec; 33(10):729-40. PubMed ID: 20444525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.